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Abstract
Fluorinated double-chain (poly)cationic lipids (one or both of these chains being ended by a highly fluorinated tail) which are close
analogues of DOTMA, DMRIE or DPPES were designed as synthetic vectors for gene delivery. For N/P ratios (N = number of amine
functions of the lipid; P= number of DNA phosphates) from 0.8 to 5, these fluorinated cationic lipids condensed DNA, with or without the
use of DOPE, to form fluorinated lipoplexes. No specific cell toxicity was evidenced for these new fluorinated lipoplexes. The efficiency of
some of the fluorinated lipoplexes to transfect lung epithelial A549 cells was comparable to that of the first generation of fluorinated
lipoplexes made from fluorinated analogues of DOGS (Transfectam) [Bioconjug. Chem. 12 (2001) 114]. These results, combined with the
higher in vivo transfection potential found for fluorinated lipoplexes than for conventional lipoplexes or PEI polyplexes [J. Gene Med. 3
(2001) 109], confirm that fluorinated lipoplexes are very promising gene transfer systems.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Synthetic nonviral gene (or DNA) transfer systems into
cells have become very promising novel forms of molecular
medicine. Although at present, the expression levels
obtained with synthetic gene transfer vectors based on
(poly)cationic lipids, liposomes, or polymers (e.g. lipo-
plexes or polyplexes, respectively [1–5]) are transient and
lower than with viral vectors, these systems present several
advantages including low-cost and large-scale production,
safety, and capacity to deliver large gene fragments. How-
ever, there is still a need for the development of lipoplexes
or polyplexes with improved and original properties.
Fluorinated lipoplexes, that is, lipoplexes formulated with
highly fluorinated lipids, are such promising transfection
systems. Indeed, highly fluorinated analogues of DOGS
(TransfectamR) [6,7] and highly fluorinated helper lipids,
analogues of dioleoylphosphatidylethanolamine (DOPE) [8],
were recently shown to lead to lipoplexes that exhibited a
higher in vitro and in vivo transfection potential than con-
ventional lipoplexes [6–8] or even than PEI polyplexes [8].
The remarkable transfection potency of the fluorinated lip-
oplexes (resulting from the formulation of DNA with fluo-
rinated cationic lipids) was attributed to the unique
lipophobic and hydrophobic character of fluorinated chains,
thus preventing DNA from interactions with lipophilic and
hydrophilic biocompounds, and from degradation [7].
We report herein on the synthesis of a series of new
highly fluorinated lipo(poly)amines (see structures in Fig. 1)
and on their abilities of compacting and transferring DNA
into cells. These new compounds are close analogues of
DOTMA [9], DMRIE [10] and DPPES [11] which are also
very frequently used as synthetic gene transfer agents. The
present study was aimed at extending the library of fluori-
nated cationic lipids that enable gene transfer. It was also
aimed at examining the transfection efficiency of the fluo-
rinated lipoplexes formulated with these new fluorinated
cationic lipids as compared with the first generation of
fluorinated DOGS analogues and with conventional cationic
lipids such as DOGS (see structures in Fig. 1).
The framework of the fluorinated analogues of DOTMA
(e.g. DF4C11-TMA) and DMRIE (e.g. DF4C11-DMHEA)
consists of a hydrophobic part, which includes two
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F(CF2)4(CH2)11 (F4C11) chains. These chains were shown
in the DOGS series to lead to the most efficient gene transfer
element (i.e. DF4C11-GS) [6]. [F8E11][C16]OPES is a
fluorinated analogue of DPPES, and contains a mixed
fluorocarbon/hydrocarbon hydrophobic framework. This
compound derives from the fluorinated [F8E11][C16]OPE
phosphoethanolamine which was found, in vitro and in
vivo, to be a more efficient helper lipid than DOPE [8].
As the use of DOPE as co-lipid was found to enhance the
transfection activity of most (poly)cationic lipids (including
the fluorinated analogues of DOGS [6]), we report also on
the transfection efficacy of DF4C11-TMA, DF4C11-
DMHEA and [F8E11][C16]OPES used in conjunction with
DOPE. The lipoplexes formulated with these new fluori-
nated cationic lipids were further compared with the most
efficient formulations made from the fluorinated DOGS
analogue, that is, DF4C11-GS, and with DOGS [6].
2. Materials and methods
2.1. General experimental and analytical conditions
Most of the reactions were performed in anhydrous
solvents under dry and oxygen-free nitrogen. Anhydrous
solvents were prepared by standard methods. The purifica-
tions by column chromatography were carried out using
silica gel 60 (Merck, 70–230 mesh) and chloroform
(CHCl3), dichloromethane (CH2Cl2), methanol (MeOH) or
mixtures thereof as indicated. Unless noted otherwise, the
ratios describing the composition of solvent mixtures rep-
resent relative volume. Advancing of the reaction was
followed by thin layer chromatography (TLC) on silica
plates F254 (Merck). The following developing systems were
used: UV light, KMnO4, H2SO4/EtOH, Dragendorff reagent
(Sigma), ninhydrin reagent (Sigma).
11-( F-butyl)undecyl toluene-4-sulfonate and tetra-
N,NV,NW,Nj-(tert-butyloxycarbonyl)-spermine-5-carboxylic
acid were synthesised according to Refs. [12] and [6],
respectively. Rac-3-[11-(F-octyl)undec-10-enyl]-2-(hexade-
cyl)glycero-1-phosphoethanolamine, [F8E11][C16]OPE,
was from our laboratory [8]. DOPE was purchased from Sig-
ma.All other organic chemicals were from Aldrich or Fluka.
1H, 13C and 19F NMR spectra were recorded at 200, 50.3,
and 188.3 MHz, respectively, on a Bruker AC-200. Chem-
ical shifts were measured relative to CHCl3 (y 7.27 ppm) or
CH3OD (y 3.35 ppm) for
1H, relative to CDCl3 (y 76.9 ppm)
for 13C and expressed indirectly in relation to TMS, and
relative to CCl3F as internal reference for
19F. The following
abbreviations are used to describe the signal multiplicities:
s (singlet), d (doublet), t (triplet), q (quadruplet), and m
(multiplet). Chemical shifts are expressed in parts per
million and listed as follows: shift in parts per million
(multiplicity, coupling, integration and attribution). Electro-
spray ionisation mass spectrometry (ESI-MS) in positive
mode was performed on a Finnigan MAT LCQ equipped
with an atmospheric pressure ionisation (API) source. Ele-
mental analyses were carried out by the Service Central de
Microanalyses du CNRS.
2.2. Synthesis of the fluorinated cationic lipids
2.2.1. N-[1-(2,3-di-11-( F-butyl)undecyloxy)propyl]-N,N,N-
trimethylammonium iodide, DF4C11-TMA
A suspension of NaH (360 mg, 15.0 mmol) and 0.6 g of
3-dimethylamino-1,2-propanediol in 50 ml of toluene was
stirred during 30 min at 50 jC. Then, 6.0 g (11 mmol) of 11-
(F-butyl)undecyl toluene-4-sulfonate was added and the
resulting mixture was heated at reflux during 24 h. After
hydrolysis, the aqueous phase was extracted with CHCl3.
The organic phase was then washed with water, dried over
Na2SO4 and evaporated. Flash chromatography of the
residue over a silica gel column (180 g, CHCl3 then
CHCl3/MeOH: 99/1: v/v) afforded 2.1 g (2.4 mmol, 58%)
of N-[1-(2,3-di-11-(F-butyl)undecyloxy)propyl]-N,N-dime-
thylamine as a colourless oil. [TLC (CHCl3/MeOH 99/1:
9/1: v/v; ninhydrin): Rf = 0.35. 1H NMR (CDCl3): y 1.18–
1.42 (s large, 28H, CF2(CH2)2(CH2)7); 1.42–1.65 (m, 8H,
CF2CH2CH2, CH2CH2O); 1.99 (tt,
3J = 7.5 Hz, 3JHF = 19.1
Hz, 4H, CF2CH2); 2.24 (s, 6H, CH3); 2.34–2.42 (m, 2H,
CH2N); 3.34–3.64 (m, 7H, CH2O, CHO).
13C NMR
Fig. 1. Chemical structure of the fluorinated and reference cationic lipids
used or mentioned in this study: DF4C11-TMA, DF4C11-DMHEA,
[F8E11][C16]OPES and DF4C11-GS [6] are fluorinated analogues of
DOTMA [9], DMRIE [10], DPPES [11] and DOGS [2], respectively.
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(CDCl3): y 20.0 (t,
3JCF = 4 Hz, CF2CH2CH2); 26.2 (CH2
(CH2)2O); 29.0, 29.1, 29.3, 29.4, 29.5, 29.6 (CF2(CH2)2
(CH2)6); 30.2 (CH2CH2O); 30.7 (t,
2JCF = 22 Hz, CF2CH2);
46.0 (CH3); 61.0 (CH2N); 70.1 (OCH2CH); 71.5, 72.0
(CH2O); 77.2 (CH).
19F NMR (CDCl3): y  81.4 (3F,
CF3);  115.2 (2F, CF2CH2);  125.0 (2F,CF3CF2CF2);
 126.5 (2F, CF3CF2)]. Then, 130 mg (0.15 mmol) of this
dimethylamine derivative in 3 ml of MeI was stirred over-
night at room temperature. After evaporation of excess MeI
and triturating with diethylether, 150 mg of DF4C11-TMA
(0.15 mmol, 100%) as a white powder was obtained. 1H
NMR (CDCl3): y 1.15–1.47 (s large, 28H, CF2(CH2)2
(CH2)7); 1.47–1.70 (m, 8H, CF2CH2CH2, CH2CH2O);
2.05 (tt, 3J = 7.5 Hz, 3JHF = 19.1 Hz, 4H, CF2CH2); 3.34–
3.73, 3.95–4.16 (m, 15H, CH2N, CH2O, CHO, CH3).
13C
NMR (CDCl3): y 20.1 (t,
3JCF = 4 Hz, CF2CH2CH2); 26.1,
26.2 (CH2(CH2)2O); 29.1, 29.2, 29.4, 29.5 (CF2(CH2)2
(CH2)6); 30.0 (CH2CH2O); 30.8 (t,
2JCF = 22 Hz, CF2CH2);
55.2 (CH3); 68.1, 68.3, 69.3, 72.1, 73.5 (CH2O, CH2N);
73.5 (CH). 19F NMR(CDCl3): identical to that of N-[1-(2,3-
di-11-( F-butyl)undecyloxy)propyl]-N,N-dimethylamine.
ESI-MS: m/z = 878.8, in agreement with the calculated mass
for [M] + =C36H58F18NO2. Anal. calc. for (C36H58F18INO2)
C, 42.99; H, 5.81; N, 1.39. Found: C, 43.28; H, 6.01; N,
1.53.
2.2.2. Synthesis of N-[1-(2,3-di-11-( F-butyl)undecyloxy)-
propyl]-N-[2-hydroxyethyl]-N,N-dimethylammonium bro-
mide, DF4C11-DMHEA
A mixture of 1.3 g (1.5 mmol) of N-[1-(2,3-di-11-(F-
butyl)undecyloxy)propyl]-N,N-dimethylamine, 0.5 ml NEt3
(3.6 mmol), 4 ml of 2-bromoethanol (56 mmol) in 50 ml of
THF was stirred during 12 h at room temperature, then
during 4 h at reflux. After filtration and evaporation, the
residue was dissolved in CH2Cl2. The organic phase was
extracted with water, dried over Na2SO4. Flash chromatog-
raphy of the residue obtained after evaporation over a silica
gel column (60 g, CH2Cl2 then CH2Cl2/MeOH: 95/5: v/v)
led to 1.2 g (1.2 mmol, 80%) of DF4C11-DMHEA as a
white powder.
TLC (CH2Cl2/MeOH: 9/1: v/v; H2SO4, Dragendorff):
Rf = 0.40. 1H NMR (CDCl3/CD3OD): y 1.12–1.44 (s large,
28H, CF2(CH2)2(CH2)7); 1.44–1.70 (m, 8H, CF2CH2CH2,
CH2CH2O); 1.99 (tt,
3J = 7.5 Hz, 3JHF = 19.1 Hz, 4H,
CF2CH2); 3.18 (s, 6H, CH3); 3.30–3.73, 3.84–4.05 (m,
13H, CH2N, CH2O, CHO).
13C NMR (CDCl3/CD3OD): y
20.6 (t, 3JCF = 4 Hz, CF2CH2CH2); 26.6, 26.7 (CH2
(CH2)2O); 29.6, 29.7, 29.8, 29.9, 30.0 (CF2(CH2)2(CH2)6);
30.6 (CH2CH2O); 31.3 (t,
2JCF = 2 Hz, CF2CH2); 53.4, 53.5
(CH3); 56.5, 67.8, 69.5, 69.9, 72.5 (CH2O, CH2N); 73.8
(CH). 19F NMR (CDCl3/CD3OD): identical to that of N-[1-
(2,3-di-11-( F-butyl)undecyloxy)propyl]-N,N-dimethyl-
amine. ESI-MS: m/z = 908.8, in agreement with the calcu-
lated mass for [M] + = C37H60F18NO3. Anal. calc. for
(C37H60BrF18NO3) C, 44.95; H, 6.12; N, 1.42. Found: C,
45.65; H, 6.25; N, 1.49.
2.2.3. Synthesis of NV-(rac-1-[11-( F-octyl)undec-10-enyl]-
2-(hexadecyl)glycero-3-phosphoethanoyl)-sperminecarbox-
amide, [F8E11][C16]OPES (as its tetra trifluoroacetate
ammonium salt)
A solution of 60 mg (0.09 mmol) tetrabutyloxycarbonyl-
spermine carboxylic acid [6], 19 mg (0.095 mmol) of N-
hydroxysuccinimide (HOSu) and 11 mg (0.095 mmol) of
dicyclohexylcarbodiimide (DCC) in 2 ml of CH2Cl2 was
stirred at room temperature during 12 h. The mixture was
cooled to 0 jC and filtrated. Then, 100 mg (0.083 mmol) of
[F811][C16]OPE (F-PE) and 40 Al (0.30 mmol) of NEt3
were added and the resulting mixture was stirred at room
temperature during 12 h. The organic phase was washed
with water, dried over Na2SO4. Flash chromatography of the
residue obtained after evaporation over a silica gel column
(10 g, CH2Cl2/MeOH 99/1 to 9/1: v/v) led to 70 mg (0.043
mmol, 53%) of NV-(rac-1-[11-(F-octyl)undec-10-enyl]-2-
(hexadecyl)glycero-3-phosphoethanoyl)-tetrabutoxycarbo-
nylspermine-carboxamide, [F8E11][C16]OPES(Boc) as a
colourless oil. TLC (CH2Cl2/MeOH: 9/1: v/v; ninhydrin):
Rf = 0.48. 1H NMR (CDCl3): y 0.89 (t,
3J = 6.1 Hz, 3H, CH3);
1.08–1.38 (s large, 38H, CH3(CH2)13, (CH2)6(CH2)2O);
1.38 – 1.88 (m, 48H, CH2CH2O, CH3 (Boc), CH2
CH2N(H)Boc, CHCH2CH2) ; 2 .11 – 2.29 (m, 2H,
CHMCHCH2); 2.87–3.35 (m, 10H, CH2NBoc, CH2N
(H)Boc);3.35–3.71(m,11H,CH2N(H)C(O),CH,CH2OCH2,
CH2OCH); 3.71–4.12 (m, 4H, CHCH2OP, POCH2CH2N);
5.46–5.73 (m, 1H, CF2CHMCH); 6.27–6.52 (m, 1H,
CF2CHMCH).
13C NMR (CDCl3): y 14.0 (CH3); 22.7
(CH3CH2); 26.2 (CH2CH2CH2O); 28.4 (CH3 (Boc)); 28.0,
29.1, 29.4, 29.6, 29.8, 30.2 (CH2CH2O, CH3(CH2)2(CH2)10,
CHMCHCH2(CH2)5); 31.9, 32.0 (CH3CH2CH2, MCHCH2);
40.2 (OCH2CH2N); 64.1 (d,
2JCP = 5 Hz, POCH2CH2N);
65.2 (d, 2JCP= 5 Hz, CHCH2OP); 70.6, 71.7 (CH2OCH2,
CH2OCH); 77.7 (d,
3JCP = 8 Hz, CHO); 78.6, 79.5, 80.8
(C(CH3)3); 116.7 (t,
2JCF = 23 Hz, CF2CHMCH); 143.0 (t,
3JCF = 9 Hz, CF2CHMCH trans); 156.5 (C(O)); 171.5
(NC(O)CH). The spermine CH2 and CH resonances appear
as large signals between 37 and 47 ppm. 19F NMR (CDCl3):
y  81.2 (3F, CF3);  106.8 (0.2F, CF2CH cis);  111.6
(1.8F, CF2CH trans);  121.9,  122.4,  123.2,  123.9
(2F, 4F, 2F, 2F, CF3CF2(CF2)5);  126.6 (2F, CF3CF2). 31P
{1H} NMR (CDCl3): y  2.45 (s).
The Boc-deprotection was quantitatively achieved by
dissolving and keeping [F8E11][C16]OPES(Boc) in a large
excess of TFA at room temperature for 1 h. The excess TFA
was removed by co-evaporation in the presence of cyclo-
hexane. Then, the product was triturated in CH2Cl2 to give
the desired [F8E11][C16]OPES lipospermine, as its tetra-
TFA ammonium salt.
1H NMR (CD3OD): y 0.89 (t,
3J = 6.1 Hz, 3H, CH3);
1.17–1.71 (s large, 42H, CH3(CH2)14, (CH2)7CH2O); 1.71–
2.38 (m, 10 H, MCHCH2, CHCH2CH2, CH2CH2N
+ ); 2.89
–3.27 (m, 10H, CH2N
+ ); 3.40–3.72 (m, 9H, CH2O, CHO,
CH2N(H)C(O)); 3.71–4.12 (m, 4H, CHCH2OP, POCH2
CH2, C(O)CH); 5.46–5.73 (m, 1H, CF2CHMCH); 6.27–
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6.52 (m, 1H, CF2CHMCH).
13C NMR (CD3OD): y 14.4
(CH3); 22.7, 28.5 (CHCH2CH2); 23.7 (CH3CH2); 27.3
(CH2CH2CH2O); 25.4 (CH2CH2N
+ ); 29.2, 30.1, 30.2,
30.3, 30.4, 30.5, 30.6, 30.7, 30.8 (CH2CH2O, CH3(CH2)2
(CH2)10, CHMCHCH2(CH2)5); 33.0, 33.1 (CH3CH2CH2,
MCHCH2); 37.8, 37.9, 45.0, 45.7 (CH2N
+ ); 41.5 (d, 3JCP= 6
Hz, CH2N(H)C(O)); 61.5 (C(O)CH); 64.9, 66.5 (CHCH2
OP, POCH2CH2); 71.6, 71.7, 72.7 (CH2OCH2, CH2OCH);
79.0 (d, 3JCP= 8 Hz, CHCH2OP); 117.3 (t,
2JCF = 23 Hz,
CF2CHMCH); 145.4 (t,
3JCF = 9 Hz, CF2CHMCH); 168.4
(C(O)N(H)). 19F NMR (CD3OD): y  76.0 (13.5F, CF3
C(O)O);  81.3 (3F, CF3);  106.8 (0.2F, CF2CH cis);
 111.7 (1.8F, CF2CH trans);  121.9,  122.5,  123.4,
 123.9 (2F, 4F, 2F, 2F, CF3CF2(CF2)5);  126.7 (2F,
CF3CF2).
31P {1H} NMR (CD3OD): y  2.32 (s). ESI-MS:
m/z = 1237.2, in agreement with the calculated mass for
[M+Na] + =C49H90F17N5O7P +Na
+ .
2.3. Preparation of DNA complexes
The plasmid pTG11033 (pCMV-intronHMG-luciferase-
SV40pA), used for the preparation of the DNA complexes
and for transfection assays, was produced by Transge`ne
(Strasbourg, France). pTG11033 is a plasmid of 9572 bp.
The endotoxin content of the plasmid preparation was
checked using a Limulus Amebocyte Lysat kit (Biogenic,
France). This value was below 1 endotoxin unit/mg of
plasmid, hence below the 5 e.u./mg of DNA recommended
for in vivo protocols. The quantities of compound used were
calculated according to the desired DNA concentration of
0.1 mg/ml, the N/P ratio, the molar weight and the number
of positive charges in the selected cationic lipid (CL). The
N/P ratio of 5, for example, corresponds to the molar
amount of CL necessary to have a ratio of five amino group
nitrogens (for 1 mol CL) per one phosphate in the DNA
(330 Da mean Mw), as described elsewhere [1,13,14]. The
CL/DNA complex is formulated by adding a desired volume
of the CL preparation at a concentration of 10 mg/ml (in 20
mM HEPES buffer, pH 7.5) to the desired volume of DNA
solution to reach desired DNA concentration (e.g. 0.1 mg/
ml). Thus, for the preparation of the [F8E11][C16]OPES/
DNA complex at N/P ratio 5 and 0.1 mg/ml DNA, 50 Al of a
[F8E11][C16]OPES solution (10 mg/ml in EtOH) was
transferred to a borosilicate glass tube (16 100 mm).
The solvent was evaporated in a Rotavap evaporation
system (45 jC, 30 pm, 0.2 bar, 40 min). Fifty microliters
of HEPES 20 mM, pH 7.5 was added to the film obtained.
The preparation was vortexed for 12 h. Then, 47.9 Al of this
preparation was added to 952.1 Al DNA solution [100 Al
DNA (1 mg/ml) diluted with 852.1 Al HEPES buffer]. This
preparation was vortexed for 10 s and was used within 1 h
for the particle size measurements and the in vitro trans-
fection experiments.
When the composition further comprises DOPE, the
desired volume of 10 mg/ml chloroform solution (to get
1:1 CL/DOPE, mol/mol ) was added to the volume of CL
solution (10 mg/ml in EtOH) and then the mixture was
transferred to a borosilicate glass tube. The following steps
were as described above.
2.4. Measurement of the size of the lipoplexes
The sample was diluted with HEPES 20 mM in the
measurement tube and homogenised and the average sizes
were measured by photon correlation spectroscopy using a
Coulter N4Plus particle size analyser, as described else-
where [5,6]. The formulations and analyses were reproduced
twice.
2.5. Agarose gel electrophoresis
Each sample was analysed and plasmid integrity in each
sample was confirmed by electrophoresis after decomplex-
ing the lipoplexes with sodium dodecyl sulfate, following
the procedures described elsewhere [5,6].
2.6. In vitro transfection of A549 cells
The same transfection protocol as that described for the
fluorinated analogues of DOGS was used [6]. Briefly, 24 h
before transfection, A549 cells (epithelial cells derived from
human pulmonary carcinoma) were grown in Dulbecco’s
modified Eagle culture medium (DMEM) (GIBCO-BRL,
Life Technologies, Cergy Pontoise, France), containing 10%
foetal calf serum, FCS (Sigma, Saint Quentin Fallavier,
France), in 96-well plates (2 104 cells per well), in a wet
(37 jC) and 5% CO2/95% air atmosphere. Volume of DNA/
CL:DOPE (1:x, x = 0, 1 mol) lipoplex (10, 5 and 1 Al) was
diluted to 100 Al in DMEM supplemented with 10% FCS to
obtain various amounts of DNA (1, 0.5 and 0.1 Ag, respec-
tively) in the preparation. The culture medium was removed
and replaced by 100 Al of DMEM supplemented with 10%
FCS and containing the desired amount of DNA. After 4 and
24 h, 50 and 100 Al of DMEM supplemented with 30% and
10% FCS, respectively, were added. After transfection (48
h), the culture medium was discarded and the cells were
washed twice with 100 Al of PBS and then lysed with 50 Al
of lysis buffer (Promega, Charbonnie`res, France). The
lysates were frozen at  40 jC awaiting analysis of lucifer-
ase activity. These measurements were done for 10 s on 10 Al
of the lysis mixture in a Berthold LB96P luminometer in
dynamic mode, using the ‘‘Luciferase’’ determination sys-
tem (Promega) in 96-well plates. The total protein concen-
tration per well was determined using conventional
techniques (BCA test, Pierce, Montlucon, France). For cells
grown in the absence of lipoplexes, a well contains around
30–50 Ag of proteins. The percentage of cell viability of the
lipoplexes was calculated as the ratio of the total protein
amount per well of the transfected cells relative to that
measured for untreated cells 100%. The given means
F S.E.M. were calculated from two or three repetitions in
two independent experiments.
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2.7. Statistical analyses
Statistical tests were performed with STATGRAPHICS
Plus5.0R software. Analysis of variance (ANOVA) was run
on the logarithmic transformation of transfection levels
[Log10(femtograms luciferase/milligram protein)] and on
the cell viability to fit normal distributions of the data.
For the fluorinated DF4C11-TMA, DF4C11-DMHEA
and [F8E11][C16]OPES lipids, three factors, that is, DOPE
(added or not), DNA amount/well (0.1, 0.5 and 1 Ag/well)
and N/P ratio (5, 2.5, 1.25 and 0.8), were analysed as source
of the variation of cell viability percentages and of logarith-
mic transformation of the transfection levels. When two- or
three-way interactions ( p < 0.05) between factors were found
to be statistically significant, multiple comparison procedure
[Tukey’s Honestly Significant Difference (HSD)] was used
to isolate which factor levels differed from the others.
To compare the transfection efficiencies and the effects
on cell viability of these new fluorinated lipids to those of
DF4C11-GS and DOGS, a multiple-sample comparison
procedure was run. The method being used to discriminate
among the means was HSD procedure.
3. Results and discussion
3.1. Synthesis
The syntheses of the fluorinated (poly)cationic lipids
DF4C11-TMA, DF4C11-DMHEA and [F8E11][C16]OPES
were performed using the procedures described for their
respective hydrocarbon DOTMA [9], DMRIE [10] and
DPPES [11] analogues and are shown in Schemes 1 and
2. Their specificity lies in the use of perfluoroalkylated
derivatives which are not commercially available. The first
step of the synthesis of DF4C11-TMA and DF4C11-
DMHEA was common to both derivatives (Scheme 1). It
consisted into the O-alkylation of the dianion of 3-dimethy-
lamino-1,2-propanediol using 11-(F-butyl)undecyl tosylate
[9]. Quaternarisation of the amine function using a large
excess of methyl iodide or 2-bromoethanol afforded
DF4C11-TMA or DF4C11-DMHEA, respectively.
The synthesis of the fluorinated lipospermines [F8E11]
[C16]OPES (isolated as its tetra-TFA ammonium salt, as
attested by 19F NMR) was achieved by coupling the fluori-
nated glycerophosphoethanolamine [F8E11][C16]OPE [8]
with tetra-tert-butoxycarbonylspermine-5-carboxylic acid
[6] in the presence of DCC/HOSu as coupling agent,
followed by the quantitative Boc-deprotection with TFA
[6,11]. The characterisation and purification of this highly
hygroscopic tetra-TFA ammonium salt was best performed
on the Boc-protected derivative.
3.2. Lipoplex formation and characterisation
The capability of the various fluorinated lipids (F-lipids)
to condense DNA and to form lipoplexes was analysed with
or without an equimolar amount of DOPE. These studies
were performed with pTG11033 plasmid, also used for the
in vitro transfection assays (see below). The procedure
applied for the lipoplex preparation relies on the dilution
from a micellar or liposomal F-lipid or F-lipid/DOPE 1:1
mol dispersion in buffer, using N/P ratios of 5, 2.5, 1.25 and
0.8. The sizes of the lipoplexes were analysed by light
scattering spectroscopy (LSS). Table 1 collects the mean
particle sizes measured for the different lipoplexes.
For an excess of cationic charges, such as N/P ratios of
2.5 and 5, all the fluorinated aminolipids condensed DNA
into cationic lipoplexes with mean particle sizes in the 170–
220 nm range, except for DF4C11-TMA for which precip-
Scheme 1. Synthetic route to DF4C11-TMA and DF4C11-DMHEA. (i)
NaH/toluene, then F(CF2)4(CH2)11OTs; (ii) excess MeI; (iii) excess
BrCH2CH2OH, NEt3, THF.
Scheme 2. Synthetic route to the fluorinated [F8E11][C16]OPES lip-
ospermine. (i) DCC/HOSu, CH2Cl2/THF; (ii) excess TFA/CH2Cl2.
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itates were observed. Co-formulation of the N/P 2.5 and 5
lipoplexes with an equimolar amount of DOPE resulted in a
lipoplex size increase (200–400 nm), although for the
[F8E11][C16]OPES/DOPE N/P 2.5 complexes, a precipitate
formed.
For N/P 1.25, and with or without the addition of DOPE,
one observed often precipitates. For N/P 0.8, the fluorinated
lipo(poly)amines condensed DNA into ‘‘anionic’’ lipo-
plexes of a mean size in the 300- to 460-nm range. The
addition of an equimolar amount of DOPE had no signifi-
cant effect on lipoplex size (320–550 nm).
Altogether, these results in terms of impact of N/P ratio
on lipoplex stability, that is, formation of precipitates for N/
P 1.25 corresponding to ‘‘neutrally’’ charged lipoplexes and
‘‘stable’’ dispersions for N/P ratios corresponding to neg-
atively and positively charged lipoplexes, are close to those
reported for other lipopolyamines [15] and for the fluori-
nated analogues of DOGS [6] (see data for DF4C11-GS in
Table 1).
These formulations were also analysed by gel electro-
phoresis (results not shown) which indicated the presence of
‘‘free’’ plasmid and of complexed plasmid accessible to
ethidium bromide intercalation for the DF4C11-TMA and
DF4C11-DMHEA formulations, even for the highest N/P
ratio investigated (N/P 5). When DOPE was used as co-lipid
of DF4C11-TMA and DF4C11-DMHEA, only the N/P 0.8
and 1.25 formulations displayed ‘‘free’’ and accessible
plasmid. By contrast, the DNA was totally protected from
ethidium bromide interaction for the [F8E11][C16]OPES
lipoplexes, with or without DOPE, except for N/P 0.8.
3.3. In vitro transfection
The transfection potential of DF4C11-TMA, DF4C11-
DMHEA and [F8E11][C16]OPES, without and with an
equimolar amount of DOPE, was assayed in vitro on
A549 cells. These assays were performed by incubating
the lipoplexes with the cells in the presence of 10% foetal
calf serum for 24 h. All N/P 0.8, 1.25, 2.5 and 5 lipoplex
formulations, even those that precipitated, were tested. Their
transfection efficiency [expressed in femtograms (fg) of
luciferase/milligram (mg) of protein] was evaluated for a
DNA amount of 0.1, 0.5 and 1 Ag/well as compared to
naked DNA and to reference lipoplexes based on DF4C11-
GS or DOGS (without and with an equimolar amount of
DOPE). Cells treated with naked DNA under equivalent
conditions showed expression levels of about 102–3 fg of
luciferase/mg of protein. The cell viability of the lipoplexes
was also checked by determining the total protein amount
per well of the transfected cells relative to that measured for
untreated cells (for which the total protein amount per well
is in a 30- to 60-Ag/well range).
Fig. 2 presents the transfection results for the fluorinated
lipoplexes formulated without and with an equimolar
amount of DOPE obtained for a DNA amount of 0.1, 0.5
and 1 Ag/well. As for most of the conventional (poly)ca-
tionic lipids tested so far, the transfection efficiency and the
cell tolerance of the fluorinated lipoplexes were related to
the concentration of the lipoplexes (expressed as DNA
amount/well) and the lipoplex formulation (DOPE added
or not, N/P ratio).
The variance analysis of the logarithmic transformation
of the transfection levels obtained with the fluorinated
lipoplexes showed that three factors (DOPE added or not,
DNA amount/well and N/P ratio of the lipoplexes) had
significant effects on their variability ( p < 0.001; data not
shown; see also discussion below). The two factors con-
tributing the most to the variance were the concentration of
the lipoplexes (DNA) and the use of DOPE for the
formulation of the lipoplexes. Furthermore, the variance
analysis showed also a high two-way interaction between
the DOPE and N/P ratio factors ( p < 0.001; data not
shown), indicating that the effect of DOPE on the trans-
fection level depended on the N/P ratio used for the
formulation of the lipoplexes.
Concerning the toxicity of the lipoplexes, the variance
analysis of cell survival showed in the case of DF4C11-
DMHEA and DF4C11-TMA that the factors having the
highest impact on variance were the DNA concentration and
DOPE factors ( p < 0.001; data not shown). Two two-way
interactions were also found, one between the DOPE and
DNA concentration factors, and another one between the
DOPE and N/P ratio factors, indicating that the effect of
DOPE on cell survival of the lipoplexes depended on the
DNA concentration and on the N/P ratio of these lipoplexes.
For [F8E11][C16]OPES, the DNA concentration and N/P
ratio factors had the main contribution to the variability
Table 1
Mean size of the lipoplexes formed between plasmid pTG11033 and
DF4C11-TMA, DF4C11-DMHEA, or [F8E11][C16]OPES, as determined
by light scattering spectroscopy
Cationic lipid N/P ratioa Lipoplexes
Mean diameter in nanometers (S.D.)
Without DOPE With DOPE
DF4C11-TMA 5 pb 300 (110)
2.5 pb 400 (150)
1.25 340 (110) pb
0.8 300 (90) 460 (170)
DF4C11-DMHEA 5 160 (large) 300 (110)
2.5 220 (large) 325 (110)
1.25 pb pb
0.8 380 (130) 450 (150)
[F8E11][C16]OPES 5 170 (60) 200 (75)
2.5 180 (60) pb
1.25 pb pb
0.8 370 (130) 350 (130)
DF4C11-GS 5 125 (40) 280 (80)
2.5 pb pb
1.25 pb pb
0.8 340 (120) 340 (120)
The data concerning the DF4C11-GS formulations were taken from Ref.
[6].
a N = lipid cation equivalents; P= plasmid phosphate equivalents.
b p = precipitate.
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of cell survival ( p< 0.001) while DOPE had no impact
( p > 0.05; data not shown).
Analysing means of transfection values with respect to the
concentration of the lipoplexes, it appears, as illustrated in
Fig. 3, panels A1–3, that the transfection efficiency of the
fluorinated lipoplexes significantly increased on raising the
DNA concentration from 0.1 to 0.5 and to 1 Ag/well
( p < 0.05). An optimum of gene expression was attained
for a DNA amount of 0.5 Ag/well ( p>0.05 between 0.5 and 1
Ag/well). It is further noteworthy that these fluorinated lip-
oplexes allowed luciferase expression levels often compat-
ible with cell growth (cell viability percentages between
77F 1% and 92F 1% for 0.5 Ag DNA/well which declined
to 59F 1% to 80F 1% for 1 Ag DNA/well; see Fig. 4, panels
A1–3).
Co-formulation of the lipoplexes with DOPE increased
significantly the transfection efficiency of the three new
fluorinated lipids tested ( p < 0.001; see Fig. 3, panels B1–3)
as for most of the conventional (poly)cationic lipids tested
so far, highlighting again the unique properties of DOPE as
helper lipid. The difference of means showed that the helper
effect of DOPE was the highest for DF4C11-DMHEA (Fig.
3, panel B3) and the lowest for DF4C11-TMA (Fig. 3, panel
B2). Co-formulation of the lipoplexes with DOPE decreased
however significantly cell viability in the case of DF4C11-
TMA and DF4C11-DMHEA ( p< 0.05; Fig. 4, panels B2
and 3) but had no significant effect in the case of
[F8E11][C16]OPES lipoplexes ( p>0.05; Fig. 4, panel B1).
The concomitant rise of transfection efficiency and toxicity
when co-formulating the DF4C11-DMHEA and DF4C11-
TMA lipoplexes with DOPE is likely related to an increase
of the lipoplex cellular uptake.
Analysing means of transfection values with respect to
the charge of the lipoplexes (N/P ratio), no systematic trend
could be evidenced with increasing the N/P ratio from 0.8 to
5 (Fig. 3, panels C1–3). One can, however, notice that the
[F8E11][C16]OPES- and DF4C11-TMA-based lipoplexes
behave very similarly, the highest mean levels of trans-
fection being attained for the N/P ratio of 0.8 and 2.5.
Surprisingly in the case of DF4C11-DMHEA, transfection
decreased with increasing the N/P ratio from 0.8–2.5 to 5
(Fig. 3, panel C3). For the formulations based on the
[F8E11][C16]OPES- and DF4C11-TMA lipids, their cell
viability was lower for the cationic N/P 2.5 and 5 lipoplexes
than for the ‘‘negative’’ (N/P 0.8) and ‘‘neutral’’ (N/P 1.25)
ones (Fig. 4, panels C1 and 2). By contrast, for DF4C11-
Fig. 2. Luciferase expression (bars) and cell viability (squares) of the fluorinated lipoplexes made of pTG11033 and DF4C11-TMA, DF4C11-DMHEA or
[F8E11][C16]OPES without and with an equimolar amount of DOPE, as compared to DOGS or DF4C11-GS controls in A549 cells for a lipoplex
concentration of 0.1, 0.5 and 1 Ag/well (panels A, B and C, respectively). Lipofection was performed in the presence of 10% foetal calf serum. MeansF S.E.M.
are given.
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DMHEA lipid, the most toxic formulations were those
corresponding to the ‘‘negative’’ (N/P 0.8) ones (Fig. 4,
panel C3).
It is further noticeable that several N/P 0.8 or 1.25
lipoplexes investigated displayed comparable luciferase
expression levels ( p>0.05) than the more cationic N/P 2.5
and 5 ones (see Fig. 2 and Fig. 3, panels C1–3), while
luciferase expression optimum is rather reported for N/P
ratios z 3 in the literature. One should mention that agarose
gel electrophoresis showed for most of the N/P 0.8 or 1.25
Fig. 4. Means and 95.0% Tukey HSD intervals of the cell viability for the fluorinated lipoplexes based on [F8E11][C16]OPES (line 1), DF4C11-TMA line (2),
or DF4C11-DMHEA (line 3) with respect to the lipoplex concentration (panel A), the presence (+) or not ( ) of DOPE (panel B), or to the lipoplex N/P ratio
(panel C).
Fig. 3. Means and 95.0% Tukey HSD intervals of the logarithmic transformation of transfection levels [Log10(femtograms luciferase/milligram protein)] for
the fluorinated lipoplexes based on [F8E11][C16]OPES (line 1), DF4C11-TMA (line 2), or DF4C11-DMHEA (line 3) with respect to the lipoplex
concentration (panel A), the presence (+) or not ( ) of DOPE (panel B), or to the lipoplex N/P ratio (panel C).
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DF4C11-TMA-, DF4C11-DMHEA- or [F8E11][C16]
OPES-based lipoplexes the presence of ‘‘free’’ DNA and
of complexed DNA accessible to ethidium bromide. These
results indicate that fully complexed and protected DNA is
not a prerequisite for optimal in vitro transfection. Optimal
lipofection with partially complexed DNA (N/P < 1 lip-
oplexes) was also found for DOGS:DOPE and DF4C11-
GS:DOPE controls (see Fig. 2) and reported for DMRIE
[10] and DMRIE analogues [16].
That an optimum of transfection can be obtained with
‘‘negatively’’ charged lipoplexes indicates most likely that
the charge of the DNA complex plays an important role not
only for cell entry, but also for intracytoplasmic DNA
delivery and/or traffic to the nucleus. It is generally assumed
that the synthetic lipofection systems provide non-specific
gene transfer into cells which involves electrostatic inter-
actions of the cationized DNA particles with the anionic
proteoglycans expressed on the cell surface followed by
endocytosis [17,18]. If the cell entry process is favoured
when increasing the cationic charge of the lipoplexes, the
intracytoplasmic DNA delivery and its traffic to the nucleus
seem to be favoured when the charge of the lipoplexes once
inside the cell is lowered to negative values, in agreement
with intracytoplasmic and/or intranuclear microinjection
experiments of partially (N/P < 1) or fully (N/P>1) com-
plexed DNA [19,20].
The aim of this study was also to evaluate the trans-
fection potential of the lipoplexes formulated with these new
fluorinated cationic lipids as compared with the most
efficient fluorinated cationic lipid reported so far for trans-
fecting A549 cells, that is, DF4C11-GS [6]. This fluorinated
reference lipid led to lipoplexes that were more efficient
than those resulting from its conventional DOGS analogue
(see results shown in Fig. 2, and Fig. 5A), both lipids being,
in our in vitro transfection protocol, among the most
efficient cationic lipids for transfecting A549 cells [6].
Multiple-sample comparisons were run on the logarith-
mic transformations of the transfection levels and on cell
viability percentages for each of the three new lipids tested
and for the DF4C11-GS and DOGS controls to determine
which means, hence which lipids, were significantly differ-
ent from which others. Fig. 5 summarises the calculated
means corresponding to the transfection and cell survival
data for their respective lipoplexes. As illustrated in Fig. 5A,
the new fluorinated lipids showed transfection level means,
and consequently transfection efficiencies, that are (i) com-
parable to those of DF4C11-GS ( p>0.05) and (ii) signifi-
cantly higher ( p < 0.05) than those of the conventional
DOGS lipid. If the [F8E11][C16]OPES-, DF4C11-TMA-,
DF4C11-GS- and DOGS-based lipoplexes gave comparable
mean cell viabilities ( p>0.05), these formulations display
significantly higher cell viabilities than the DF4C11-
DMHEA-based lipoplexes ( p < 0.05) (Fig. 5B).
4. Conclusion
All these results together combined with the higher in
vitro and in vivo transfection potential found for fluorinated
lipoplexes as compared with that of conventional lipoplexes
[6–8] or even of PEI polyplexes [8] confirm that fluorinated
lipoplexes are appealing and very promising candidates for
gene transfer purposes, highlighting the diversity of lipids
leading to efficient transfection. Although the in vitro results
obtained here with the fluorinated analogues of DOTMA,
DMRIE and DPPES using a standard transfection protocol
lead to no improvement over the first generation of fluori-
nated lipids (e.g. the fluorinated analogues of DOGS), they
are nevertheless very encouraging. Moreover, these in vitro
findings do not prejudge all of their in vitro and in vivo
behaviours which remain to be investigated. In addition,
these results confirm also that lipophobicity and restricted
miscibility of the lipoplex lipids with the endogenous lipids
does not preclude efficient gene transfer and expression.
This study underscores also the determinant impact of the
unique lipophobic and hydrophobic character of the fluori-
nated lipids on the transfection potency of the fluorinated
lipoplexes they form with DNA, preventing DNA from
interactions with lipophilic and hydrophilic biocompounds,
and from degradation [7].
Fig. 5. Means and 95.0% Tukey HSD intervals of the logarithmic
transformation of transfection levels [Log10(femtograms luciferase/milli-
gram protein); panel A] and of the cell viability (panel B) for the fluorinated
DF4C11-TMA-, DF4C11-DMHEA- or [F8E11][C16]OPES-based lipo-
plexes and for control formulations made with DF4C11-GS or DOGS,
irrespectively to the DNA concentration, the presence or not of DOPE, or
the lipoplex N/P ratio.
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